Eribulin Mesylate is an antitumor drug that can be used to treat patients with metastatic breast cancer. It inhibits the proliferation of cancer cells by binding tubulin and microtubules. Eribulin Mesylate can inhibit experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
Structure of 441045-17-6
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
1 mg | $1099 | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
NCT Number | Title | Condition Or Disease | Phase | Start Date | Sponsor | Status |
---|---|---|---|---|---|---|
NCT00047034 | E7389 in Treating Patients With Advanced Solid Tumors | Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | August 2002 | National Cancer Institute (NCI) | Completed |
NCT00334893 | Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | Fallopian Tube Cancer | Phase 2 | April 2006 | National Cancer Institute (NCI) | Completed |
NCT00337077 | Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | Adenocarcinoma of the Prostate | Phase 2 | November 2006 | National Cancer Institute (NCI) | Completed |
NCT00337103 | E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes | Metastatic Breast Cancer | Phase 3 | June 15, 2006 | Eisai Inc. | Completed |
NCT00337129 | S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer | Head and Neck Cancer | Phase 2 | May 2006 | National Cancer Institute (NCI) | Completed |
Eribulin Mesylate is a synthetic analog of halichondrin B and a potent ADC cytotoxin explored as an ADC payload in antibody-drug conjugates. It functions as a microtubule dynamics inhibitor, binding to the plus ends of microtubules and preventing their elongation, which leads to mitotic arrest and subsequent apoptosis. Its unique mechanism of action makes it an effective cytotoxic agent for targeted cancer therapies.
Within antibody-drug conjugates, Eribulin Mesylate can be conjugated to monoclonal antibodies using cleavable or non-cleavable linker strategies. These linkers ensure that the payload remains inactive in systemic circulation and is only released within tumor cells after internalization and enzymatic processing. This targeted release enhances the antitumor efficacy of ADCs while minimizing systemic toxicity, making Eribulin Mesylate a reliable payload for precision oncology applications.
Applications of Eribulin Mesylate include its integration into experimental ADCs targeting both solid tumors and hematologic malignancies, such as breast cancer, lung cancer, and sarcomas. Its high cytotoxic potency allows effective antitumor activity even at low drug-to-antibody ratios (DARs). Additionally, Eribulin Mesylate’s structural features support conjugation with diverse linker chemistries, optimizing stability, intracellular release, and overall performance in next-generation ADC development programs.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00660 | VCP-Eribulin | 2130869-17-7 | |
BADC-00860 | Mal-PEG2-VCP-Eribulin | 2130869-18-8 | |
BADC-01611 | Farletuzumab ecteribulin | 2407465-18-1 | |
BADC-01379 | Eribulin | 253128-41-5 |
What is Eribulin Mesylate?
Eribulin Mesylate is a synthetic microtubule dynamics inhibitor derived from halichondrin B. It interferes with tubulin polymerization, leading to mitotic blockage and apoptosis, and is utilized as a potent payload in ADC research for selective cytotoxic delivery.
2/7/2018
We would like to know how Eribulin Mesylate is used in ADC development.
Eribulin Mesylate serves as a cytotoxic payload in ADCs. It is conjugated to monoclonal antibodies targeting specific antigens, ensuring selective uptake by target cells and induction of apoptosis, while reducing systemic toxicity.
17/2/2018
Dear BOC Sciences, which linkers are suitable for Eribulin Mesylate ADCs?
Eribulin Mesylate can be coupled using cleavable linkers for intracellular release upon target cell internalization, or non-cleavable linkers to enhance stability in circulation. Linker selection affects pharmacokinetics and payload delivery efficiency.
28/8/2019
Dear Sir, may I ask what laboratory precautions are necessary when handling Eribulin Mesylate?
Due to its high cytotoxicity, Eribulin Mesylate must be handled with PPE, biosafety cabinets, and adherence to institutional safety guidelines. Proper waste disposal and containment are required to prevent accidental exposure during conjugation or experiments.
1/3/2019
Good morning! What advantages do Eribulin Mesylate ADCs provide in research applications?
Eribulin Mesylate ADCs allow targeted delivery of cytotoxic agents to cells expressing specific antigens. This improves therapeutic index, supports precision oncology research, and facilitates evaluation of novel ADC constructs in preclinical studies.
10/12/2022
— Dr. Jason Carter, Senior Scientist (USA)
Eribulin Mesylate from BOC Sciences showed high purity and excellent batch reproducibility.
28/8/2019
— Dr. Andrew Collins, Pharmaceutical Researcher (UK)
Eribulin Mesylate from BOC Sciences arrived on time and in excellent condition. It demonstrated consistent performance in our preclinical conjugation trials, reflecting reliable sourcing standards.
10/12/2022
— Dr. Markus Klein, Medicinal Chemist (Germany)
Fast delivery and detailed QC documentation for Eribulin Mesylate met all expectations.
1/3/2019
— Dr. Rebecca Shaw, Oncology Researcher (USA)
Our lab has tested Eribulin Mesylate from various vendors, but BOC Sciences provided the most reliable batch. Its solubility and purity supported efficient conjugation work with minimal troubleshooting.
2/7/2018
— Dr. William Adams, Lead Scientist (USA)
High-quality Eribulin Mesylate and responsive support. Perfect for our pipeline.
— Dr. Peter Hughes, Senior Chemist (UK)
Eribulin Mesylate from BOC Sciences was exceptionally consistent between batches. The compound’s stability allowed us to run prolonged conjugation studies without performance drift.
17/2/2018
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.